Jassim, G.A., Whitford, D.L., Hickey, A., & Carter, B. (2015). Psychological interventions for women with non-metastatic breast cancer. Cochrane Database of Systematic Reviews, 5, CD008729.
STUDY PURPOSE: To evaluate evidence for psychological interventions in women with breast cancer
TYPE OF STUDY: Meta analysis and systematic review
PHASE OF CARE: Multiple phases of care
In 24 of 28 trials, cognitive behavioral therapy was the basis of the intervention. Most studies had unclear risk of bias, and for studies aimed at anxiety and depression, quality of the evidence was graded as low. Comparison of CBT versus control across multiple studies for depression showed an overall standard mean difference (SMD) of -1.01 (p = 0.02) in favor of the CBT intervention. Only two studies examined CBT delivered individually, showing no significant benefit and high heterogeneity. Examined separately, group CBT also did not consistently show significant benefit for depression. Eight studies looked at change in anxiety. Both individual- and group-delivered CBT showed significant benefit, with an overall SMD -10.48 (p = 0.0006). CBT showed a significant positive effect for stress, and only marginal effect on quality of life.
Findings showed overall benefit of CBT for anxiety and depression in women with early-stage breast cancer
Although studies have shown that psychological interventions are more effective for individuals with psychological problems, the studies included here excluded women with psychological morbidity. There was high heterogeneity, and most studies were of low quality.
CBT delivered in a group or individual setting has been shown to have a positive effect on depression and anxiety among women with early-stage breast cancer. The strength of these results is limited by the relatively low quality of studies included in this review.
Janusch, M., Fischer, M., Marsch, W., Holzhausen, H.J., Kegel, T., & Helmbold, P. (2006). The hand-foot syndrome—A frequent secondary manifestation in antineoplastic chemotherapy. European Journal of Dermatology, 16, 494–499.
Multiple interventions can be implemented to prevent or minimize PPE, including teaching patients to avoid mechanical irritation of the skin, use topical emollient creams, and use regional cooling.
Jantunen, E., Kuittinen, T., & Nousiainen, T. (2002). A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. Leukemia and Lymphoma, 43, 1961–1965.
The study was conducted between November 1998 and February 2000.
This was a pilot, feasibility study.
The National Cancer Institute (NCI) Common Toxicity Criteria for Oral Mucositis was used to assess oral mucositis daily.
Most of the patients (9 out of 10) received the full dose of amifostine. One patient received only 780 mg/m2 because of recurrent hypotension. Significant nausea, as well as hypotension and vomiting, occurred.
Amifostine did not show a benefit for gastrointestinal toxicity or mucositis of more than grade 2.
Jang, G., Song, H.H., Park, K.U., Kim, H.S., Choi, D.R., Kwon, J.H., . . . Zang, D.Y. (2013). A phase II study to evaluate the efficacy of ramosetron, aprepitant, and dexamethasone in preventing cisplatin-induced nausea and vomiting in chemotherapy-naive cancer patients. Cancer Research and Treatment, 45(3), 172–177.
To evaluate the efficacy of ramosetron, aprepitant, and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin-based chemotherapy
On day 1, all patients received intravenous 0.6 mg ramosetron and oral 12 mg dexamethasone 30 minutes before chemotherapy, and they received 125 mg aprepitant orally one hour before chemotherapy. On days 2 and 3, patients received 80 mg aprepitant and 8 mg dexamethasone orally in the morning. On day 4, patients only received 8 mg dexamethasone. Patients could take rescue antiemetic medications at any time for vomiting or severe nausea. Antiemetic rescue medications were determined by treating physicians.
Prospective, open-label study
Complete response (CR) was achieved by 94.9% of patients in the acute phase, 92.3% in the delayed phase, and 92.3% in the overall phase. Absolute CR was achieved by 74.4% in the acute phase, 51.3% in the delayed phase, and 46.2% in the overall phase. The median nausea score during the acute phase was 0 (interquartile range [IQR] 0–1), 0 in the delayed phase (IQR 0–4), and 2 during the overall phase (IQR 0–4). On the VAS, mild nausea was observed in 10% of patients in the acute phase and 13% of patients in the delayed phase. Moderate to severe nausea was observed in 15% of patients in the acute phase and 36% of patients in the delayed phase.
The combination of ramosetron, aprepitant, and dexamethasone is an effective CINV regimen. The overwhelming majority of patients in this study achieved a complete response and experienced no nausea or vomiting in both the acute and delayed phase after chemotherapy.
Ramosetron, aprepitant, and dexamethasone is an effective regimen to prevent CINV in patients receiving cisplatin-based therapy. Almost all of the patients were able to achieve a complete response in both the acute and delayed phase after administration of chemotherapy. In this study, the majority of patients were receiving palliative care, therefore this combination of drugs should be considered for palliative care patients.
Janelsins, M.C., Peppone, L.J., Heckler, C.E., Kesler, S.R., Sprod, L.K., Atkins, J., . . . Mustian, K.M. (2015). YOCAS©® Yoga reduces self-reported memory difficulty in cancer survivors in a nationwide randomized clinical trial: Investigating relationships between memory and sleep. Integrative Cancer Therapies, 15, 263–271.
To investigate the effect of a combined hatha and restorative yoga intervention on memory in cancer survivors and to explore relationships between memory and sleep
YOCAS©® (Yoga for Cancer Survivors) is an instructor-guided standardized program that incorporates movement emphasizing restorative poses, breathing exercises, and mindfulness exercises. The intervention was offered twice a week in the late afternoon or evening over 75 minutes for a total of eight sessions. Although all the group trainers were Registered Yoga Alliance Teachers, they were also required to complete a training session, reviewing a detailed YOCAS©® manual to facilitate standardization across sites.
PHASE OF CARE: Late effects and survivorship
Secondary analysis of a randomized, clinical trial
At baseline, the average score on the MDASI indicated only a mild level of perceived memory problems overall. Although both groups continued to report memory problems as being mild, a significant decrease (p < 0.05) was observed in patients who completed the intervention. This difference continued to be significant when controlling for differences in age, gender, educational level, past treatment regimen, current hormonal therapy, baseline memory, and baseline sleep scores. Of note, those who received the intervention also had improved sleep (p < 0.05), which accounted for approximately 26% of the improvement in memory (p = 0.039).
Although yoga appeared to decrease perceived memory problems, this outcome was based on a single item of the MDASI. Further longitudinal studies designed specifically to measure the effect of yoga on cognitive function as measured by both objective and subjective measures are warranted.
Although this study suggested that yoga may improve patients’ perception of memory problems, some of the benefit was because of better sleep.
Jane, S.W., Chen, S.L., Wilkie, D.J., Lin, Y.C., Foreman, S.W., Beaton, R.D., . . . Liao, M.N. (2011). Effects of massage on pain, mood status, relaxation, and sleep in Taiwanese patients with metastatic bone pain: A randomized clinical trial. Pain, 152, 2432–2442.
To compare the efficacy of massage therapy to a social attention condition in Taiwanese patients with cancer with bone metastases
The study was a randomized, controlled clinical trial.
This trial documented therapeutic effects of massage on improving pain intensity, mood status, and muscle relaxation in patients with metastatic bone pain. The study has clinical implications supporting massage therapy and other medical modalities for optimal improvement in patients with cancer with bone metastases.
Massage therapy may play an important role in cancer bone pain, sleep, and, mood.
Jandhyala, R., & Fullarton, J. (2012). Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: An indirect mixed treatment comparison meta-analysis. BMJ Supportive and Palliative Care, 2, 156–162.
PHASE OF CARE: Multiple phases of care (not reported)
APPLICATIONS: Palliative care
No head to head trials between products existed. FBT produced a greater improvement in PID in the first 60 minutes after dosing (66% more probable than ODT and 68% more than OTFC). ODT and OTFC showed similar benefits, and ODT had a slightly higher benefit with a 53% probability of pain relief at 60 minutes. The two agents compared with morphine sulfate immediate-release, FBT and ODT, were compared, and benefits were significant within 15 minutes after dosing.
FBT may be advantageous as a fentanyl product, as it showed an advantage over ODT and OTFC.
Two of the trials compared FBT to a placebo, so more paitents received FBT. Therefore, cell sizes were not similar, resulting in an unequal comparison. Seven transmucosal immediate-release fentanyl (TIRF) studies existed. Only three were used in the comparison. Limited databases were searched.
Some TIRF products may have better efficacy compared to others. This analysis showed that FBT had an advantage. All products were shown to be superior to morphine in achieving pain relief one hour after dosing. Additional head to head comparison studies are needed.
Jandhyala, R., Fullarton, J.R., & Bennett, M.I. (2013). Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: A meta-analysis of comparative trials. Journal of Pain and Symptom Management, 46, 573–580.
STUDY PURPOSE: To evaluate the efficacy of oral fentanyl combinations for breakthrough cancer-related pain
TYPE OF STUDY: Meta-analysis and systematic review
DATABASES USED: PubMed
KEYWORDS: breakthrough cancer pain; incident pain; pain flare; morphine; fentanyl
INCLUSION CRITERIA: RCT
EXCLUSION CRITERIA: Not specified
TOTAL REFERENCES RETRIEVED: Not stated
EVALUATION METHOD AND COMMENTS ON LITERATURE USED: Not stated
APPLICATIONS: Palliative care
The probability of superior relief of breakthrough pain by differences in pain intensity scores at 15- and 60-minute intervals was calculated for immediate-release morphine and fentanyl preparations, versus placebo and versus each other. There was a 61% probability that morphine would produce a better outcome than placebo. Corresponding results versus placebo for fentanyl buccal tablet (FBT) was 97%, for orally disintegrating tablet (ODT) was 72%, and for transmucosal oral fentanyl (OTF) tablet was 81%. The probability of superiority of fentanyl over morphine during the first 60 minutes was 68% for FBT, 57% for ODT, and 66% for OTF. Pain intensity differences were larger for fentanyl preparations than for morphine when compared to placebo.
Findings suggest that oral fentanyl preparations may provide better relief of breakthrough pain during the first 60 minutes than immediate-release oral morphine.
Findings suggest that oral fentanyl preparations may be more effective for management of breakthrough pain than oral immediate-release morphine. It should be noted however, that the duration of effect with morphine could be longer because of differences in half-life. Onset, intensity, and duration of relief of breakthrough pain with various approaches need to be evaluated to determine the best approach for individual patients.
Jain, S., Pavlik, D., Distefan, J., Bruyere, R. L., Acer, J., Garcia, R., . . . Mills, P. J. (2012). Complementary medicine for fatigue and cortisol variability in breast cancer survivors: a randomized controlled trial. Cancer, 118, 777–787.
To examine, within a blinded, randomized, controlled trial design, whether biofield therapy (hands-on healing) would significantly reduce fatigue in survivors with persistent cancer-related fatigue compared to mock healing and a wait-list control group.
Energy chelation (hands-on-healing with standard hand positions focusing for five to seven minutes over each body part, i.e., feet, hips, knees, bladder, stomach, hands, elbows, shoulders, heart, throat, head, and heart) for one hour, two times each week for four weeks in the intervention group; mock biofield therapy for one hour, two times each week for four weeks; and a wait-list with no specific intervention. All participants submitted saliva samples at four time points. Timing of self-reported measures of quality of life (QOL) and depression were not reported.
The study used a blinded, randomized, controlled design.
Nonspecific factors are important in responses to biofield interventions for fatigue. Belief predicts QOL responses but not fatigue or cortisol variability. Biofield therapies increase cortisol variability independent of belief and other nonspecific factors. A need exists to further examine the effects of specific processes of biofield healing on outcomes for cancer populations.
Use of a hands-on healing intervention takes time and a skill set not traditionally taught in undergraduate or graduate nursing programs. Few clinical nurses have the time or skills to practice hands-on healing as described in the study. The intervention is noninvasive and a potentially effective independent nursing intervention with a minimal side effect profile.
Jain, S., & Mills, P. J. (2010). Biofield therapies: helpful or full of hype? A best evidence synthesis. International Journal of Behavioral Medicine, 17, 1–16.
To determine whether biofield therapies affect positive health outcomes and reduce disease symptoms.
Databases searched were PubMed, CINAHL, PyscINFO, and Allied and Complementary Medicine (AMED).
Search keywords were spiritual healing, subtle energy, energy healing, biofield healing, external qi therapy, emitted chi, emitted qi, qi therapy, Johrei, pranic healing, polarity therapy, Reiki, therapeutic touch, and healing touch. Investigators also manually searched the reference sections of studies and review papers.
Studies were included if they
Studies were excluded if they related to distant healing or intercessory prayer; integrated modalities that were not biofield-based modalities with biofield-based modalities in such a way that the interventions could not be separated; were animal, plant, and/or in vitro studies; were clinical studies with group assignment but without randomization; were purely descriptive studies; or were unpublished dissertations.
Patients were undergoing the active treatment phase of care.
The authors presented results according to type of patient and levels of evidence.
Proximally practiced biofield therapies are promising complementary interventions as means of reducing pain intensity in multiple populations, reducing anxiety in hospitalized populations, and reducing agitated behaviors in patients with dementia. The long-term effects of the therapies on fatigue and autonomic nervous system activity are unclear.
Future research should compare biofield therapies with empirically supported treatments for specific conditions.